Skip to Content
Merck
  • Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine.

Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine.

The Journal of clinical investigation (1981-11-01)
P D Henry, K I Bentley
ABSTRACT

We tested the effects of nifedipine, a calcium antagonist, on atherogenesis in rabbits fed a 2% cholesterol diet. The drug was given orally, 40 mg/dl, and control rabbits received placebo. Nifedipine was well tolerated, and evoked only transient, moderate reductions in arterial pressure. Plasma total cholesterol after 8 wk before killing the rabbits was similar in the placebo and nifedipine-treated groups, averaging 1,903 +/- 138 (n = 13) and 1,848 +/- 121 mg/dl (n = 13; mean +/- SE; P greater than 0.8). In placebo-treated rabbits, aortic lesions stainable with Sudan IV covered 40 +/- 5% of the intimal surface, and the cholesterol concentration in aortic tissue was 47 +/- 5 mg/g protein. Corresponding values for the aortas from nifedipine-treated rabbits were significantly lower and averaged 17 +/- 3% (P less than 0.001) and 29 +/- 2 mg/g protein (P less than 0.001). We conclude that nifedipine suppressed atherogenesis without reducing hypercholesterolemia.

MATERIALS
Product Number
Brand
Product Description

USP
Nifedipine, United States Pharmacopeia (USP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity